Syndax Pharmaceuticals (SNDX) Tops Q4 EPS, Revenue

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of $1.81, $1.53 better than the analyst estimate of $0.28. Revenue for the quarter came in at $126.6 million versus the consensus estimate of $58.68 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
• Farmmi announces public offering of Class A ordinary shares